Oxygen reactive polymers for treatment of traumatic brain injury

Patent metadata

Field	Value
Publication number	US-11065272-B2
Application number	US-201615766314-A
Country	US
Kind code	B2
Filing date	Oct 6, 2016
Priority date	Oct 6, 2015
Publication date	Jul 20, 2021
Grant date	Jul 20, 2021

Abstract

Methods and compositions for treating traumatic brain injury. The methods and compositions utilize a multi-functional oxygen reactive polymer (ORP) that includes repeating units that include a reactive oxygen species (ROS) scavenging group and a polyalkylene oxide group. For theranostic applications, the oxygen reactive polymer further includes a diagnostic group.

First claim

The invention claimed is:

1. A method for treating traumatic brain injury, comprising administering a therapeutically effective amount of an oxygen reactive copolymer to a subject in need thereof, wherein the oxygen reactive copolymer
has the formula

wherein
n is an integer from 1 to 12,
m is an integer from 0 to 12, and
p is an integer from 6 to 40; and
*represents the remainder of the copolymer.

2. The method of claim 1 , wherein treating traumatic brain injury comprises reducing neurodegeneration.

3. The method of claim 1 , wherein treating traumatic brain injury comprises altering gliosis.

4. The method of claim 1 , wherein treating traumatic brain injury comprises treating the secondary effects of traumatic brain injury.

5. The method of claim 1 , wherein treating traumatic brain injury comprises treating one or more of reperfusion injury, delayed cortical edema, blood-brain barrier breakdown, local electrolyte imbalance, neurovascular unit dysfunction, and intracranial pressure.

6. The method of claim 1 , wherein administering the oxygen reactive polymer comprises intravenous, intranasal, intrathecal/intraventrical, or intracranial administration.

7. The method of claim 1 , wherein the oxygen reactive polymer is in the form of a nanoparticle.

8. The method of claim 7 , wherein the nanoparticle comprises a single oxygen reactive polymer.

9. The method of claim 1 , wherein the diagnostic group is a magnetic resonance imaging group, a radiolabel group, a fluorescent group, a luminescent group, an X-ray/CT group, or an ultrasound group.

10. The method of claim 1 , wherein the copolymer is a random copolymer.

11. The method of claim 1 , wherein the copolymer has a hydrodynamic diameter from about 4 to about 100 nm.

12. The method of claim 1 , wherein the copolymer has a molar mass dispersity from about 1.05 to about 1.30.

13. The method of claim 1 , wherein the copolymer has a number average molecular weight (M n ) from about 5,000 to about 100,000.

Assignees

• Univ Washington

Inventors

• Stayton Patrick S
• Ypma Menko P
• Chiarelli Peter A
• Park Joshua Sang Hun
• Ellenbogen Richard G
• Xu Julia Mengyun
• Mourad Pierre D
• Lee Donghoon
• Convertine Anthony
• Kievit Forrest M

Classifications

• A61K47/30

  Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates · CPC title

• A61K9/14

  Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)} · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title

• A61K31/765 Primary

  Polymers containing oxygen · CPC title